EDIL3

Across TCGA pan-cancer cohorts, EDIL3 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of EDIL3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where EDIL3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types EDIL3 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, PDAC, and LUAD are the cancer types where EDIL3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EDIL3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.678	<.001	10	view →
PDAC	Female	All	+0.863	<.001	8	view →
LUAD	All	All	−0.219	.001	5	view →
LSCC	All	All	−0.214	.004	3	view →
HNSC	Male	II,III,IV	+0.278	.032	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

EDIL3–CCRCC

Open the CCRCC breakdown →